Tusamitamab ravtansine
- Generic Name
- Tusamitamab ravtansine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2254086-60-5
- Unique Ingredient Identifier
- DSS3BE2ZXN
- Background
Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).
- Associated Conditions
- -
- Associated Therapies
- -
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Erasmus Medical Center
- Registration Number
- NCT05703555
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT05429762
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center Site Number : 8400002, Dallas, Texas, United States
🇪🇸Investigational Site Number : 7240002, Barcelona, Catalunya [Cataluña], Spain
🇹🇷Investigational Site Number : 7920001, Ankara, Turkey
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT05245071
- Locations
- 🇫🇷
Investigational Site Number : 2500001, Creteil, France
🇯🇵Investigational Site Number : 3920003, Sunto Gun, Shizuoka, Japan
🇯🇵Investigational Site Number : 3920005, Hirakata-shi, Osaka, Japan
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT04659603
- Locations
- 🇹🇷
Investigational Site Number : 7920004, Ankara, Turkey
🇳🇱Investigational Site Number : 5280001, Rotterdam, Netherlands
🇹🇷Investigational Site Number : 7920003, Adana, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.